Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lucia Galan, Juan Gonzalez-Moreno, José Manuel Martínez-Sesmero, Francisco Muñoz-Beamud, Maria Dolores Santos-Rubio, Diana Tran, Paul Lebeau, Michelle Stewart, Pablo Mallaina, Patricia Tarilonte, Carmen Peral & Mark H Rozenbaum. (2021) Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 967-973.
Read now
Read now
Articles from other publishers (3)
Nicholas Riley, Christopher Drudge, Morag Nelson, Anja Haltner, Michael Barnett, Simon Broadley, Helmut Butzkueven, Pamela McCombe, Anneke Van der Walt, Erin O. Y. Wong, Martin Merschhemke, Nicholas Adlard, Rob Walker & Imtiaz A. Samjoo. (2024)
Comparative efficacy of ofatumumab
versus
oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons
. Therapeutic Advances in Neurological Disorders 17.
Crossref
Crossref
Chafic Karam, Duncan Brown, Min Yang, Nicolae Done, Ibou Dieye, Ana Bozas, Montserrat Vera Llonch & James Signorovitch. (2022)
Factors associated with increased
health‐related
quality‐of‐life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen
. Muscle & Nerve 66:3, pages 319-328.
Crossref
Crossref
Imtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz & Nicholas Adlard. (2020) Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Journal of Comparative Effectiveness Research 9:18, pages 1255-1274.
Crossref
Crossref